With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Glucagon-like peptide-1 (GLP-1) and Gastric inhibitory polypeptide (GIP) while Ozempic (Semaglutide) only targets GLP-1.

Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

American pharmaceutical company Eli Lilly has launched its drug, Mounjaro, in India. Mounjaro is administered as a ...

US giant, Eli Lilly launched Mounjaro (tirzepatide) which is a prescription medicine for adults with type 2 diabetes used ...

Another popular diabetes and weight-loss drug, Ozempic (semaglutide), manufactured by Novo Nordisk, has already established a ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, ...

The global weight-loss drug market is expected to reach $150 billion in the next decade. By 2026, semaglutide (the active ...

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

Eli Lilly launches Mounjaro in India addressing diabetes-obesity crisis. Approved by CDSCO yet high costs limit accessibility ...